Medamonitor LLC

A consortium led by Children’s National Hospital announced four recipients of grants totaling $200,000 to advance pediatric medical devices. Children’s National Hospital’s Alliance for Pediatric Device Innovation (ADPI), funded through the FDA, shared the four device makers receiving grants. The devices selected improve the monitoring, diagnosis or treatment of youth suffering from substance use disorder and addiction. A panel of expert judges picked the awardees, which each receive $50,000 and opportunities for APDI support services across all phases of the medical device product lifecycle. That includes facilitating access to technical assistance from the National Institute on Drug Abuse (NIDA). “Recognizing that drug overdose is now the third leading cause of death among adolescents, we see an urgent need to support new technologies that can help families and providers address this problem,” said Children’s National VP and Chief Innovation Officer Kolaleh Eskandanian, who is also APDI’s principal investigator and program director. “We look forward to working with these grantees and see great potential in the lifesaving and life-changing impact that their technologies could make possible.” Here are the four recipients: AltruMed Philadelphia-based AltruMed created DOVE, a shoulder-mounted device designed as a safety tool for those most at risk from overdose toxicity. It comes in at a size smaller than a matchbox and employs multi-modal sensing technology. The device helps detect severe respiratory depression and alerts bystanders and first responders. Levl Brooklyn, New York-based Levl develops a remote therapeutic monitoring platform. It designed it to address the critical challenges associated with stimulant medication treatment for adolescents with attention-deficit/hyperactivity disorder, a group at greater risk for substance abuse. The company uses collected patient data for its proprietary early risk detection mechanism. It aims to enhance the safety and effectiveness of stimulant medication treatments in response to the rise in misuse and diversion among youth. Sibel Health Based in Chicago, the company already has an FDA-cleared platform called ANNE. It includes advanced wearable sensors, AI-enabled data analytics and an integrated mobile software and cloud platform for adolescents ages 12 and up. The company plans to use grant funds to modify its existing solution for use by patients and healthcare providers to detect opiate-induced respiratory depression in high-risk adolescents. Toivoa Aiming to increase access to care, reduce wait times, provide caregiver tools and offer personalized mental health support, the Washington, D.C.-based company develops an evidence-based digital therapeutic platform. It plans to use funds to modify the platform to address mental health challenges for adolescents with dual diagnoses, including mental health and substance use disorder. The company also wants to address the support needs of caregivers.